A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

This study is testing a new medication called plixorafenib to see if it can safely slow down or stop the growth of certain solid tumors and brain tumors. It is designed for people whose cancer has a specific genetic change in the BRAF gene, which helps researchers target the cancer more effectively.

This trial is open to patients aged 10 and older who have been diagnosed with solid tumors or brain/spinal cord tumors containing a specific BRAF gene mutation. You must have a stored tumor sample available for testing and be willing to undergo regular medical imaging scans.

Participants will receive the study medication, plixorafenib, which works by targeting proteins that fuel cancer cell growth. Throughout the study, you will have regular check-ups and medical imaging scans to help doctors see how your body and tumor are responding to the treatment.

The study is currently recruiting patients at medical centers in Beverly Hills, San Francisco, and Westwood, California. Please talk to your oncologist to see if this study might be a good fit for your specific health situation.